Aspira Pathlab Intrinsic Value
Aspira Pathlab (ASPIRA) median intrinsic value is ₹32.30 from 9 valuation models (range ₹22–₹64), vs current price ₹107.65 — -70.0% downside (Trading Above Calculated Value), margin of safety -100.0%. Analyse Aspira Pathlab ownership structure to track promoter, FII and institutional holdings.
ASPIRA Valuation Methods Summary — DCF, Graham Number & P/E
Aspira Pathlab intrinsic value across 9 models vs current price ₹107.65 — upside/downside and value range per method. For current market price and key ratios, visit Aspira Pathlab stock price NSE.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹32.30 | ₹25.84 - ₹38.76 | -70.0% | EPS: ₹2.64, Sector P/E: 12x |
| Book Value Method | asset | ₹21.53 | ₹19.38 - ₹23.68 | -80.0% | Book Value/Share: ₹12.00, P/B: 1.0x |
| Revenue Multiple Method | revenue | ₹32.30 | ₹29.07 - ₹35.53 | -70.0% | Revenue/Share: ₹24.00, P/S: 0.8x |
| EBITDA Multiple Method | earnings | ₹43.06 | ₹38.75 - ₹47.37 | -60.0% | EBITDA: ₹4.00Cr, EV/EBITDA: 6x |
| Simple DCF (5Y) | dcf | ₹43.06 | ₹34.45 - ₹51.67 | -60.0% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹32.30 | ₹29.07 - ₹35.53 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹32.30 | ₹29.07 - ₹35.53 | -70.0% | Revenue Growth: 6.0%, Adj P/E: 8.2x |
| ROE Based Valuation | profitability | ₹64.00 | ₹57.60 - ₹70.40 | -40.5% | ROE: 33.3%, P/E Multiple: 16x |
| Graham Defensive Method | conservative | ₹32.30 | ₹29.07 - ₹35.53 | -70.0% | EPS: ₹2.64, BVPS: ₹12.00 |
ASPIRA Intrinsic Value vs Market Price — All Valuation Models
Aspira Pathlab fair value range ₹22–₹64 vs current market price ₹107.65 across 9 valuation models. Read Aspira Pathlab dividend payments for the complete payout history and dividend yield track record.
ASPIRA Intrinsic Value Analysis — Undervalued or Overvalued?
Aspira Pathlab median intrinsic value ₹32.30, current price ₹107.65 — Trading Above Calculated Value by 70.0%, margin of safety -100.0%.
What is the intrinsic value of ASPIRA?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Aspira Pathlab (ASPIRA) is ₹32.30 (median value). With the current market price of ₹107.65, this represents a -70.0% variance from our estimated fair value.
The valuation range spans from ₹21.53 to ₹64.00, indicating ₹21.53 - ₹64.00.
Is ASPIRA undervalued or overvalued?
Based on our multi-method analysis, Aspira Pathlab (ASPIRA) appears to be trading above calculated value by approximately 70.0%.
ASPIRA Financial Health — Key Ratios vs Industry Benchmarks
Aspira Pathlab financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 1.67 | Industry Standard: 2.0+ | Above 1.5 | Measures short-term liquidity capacity |
| Return on Equity | 33.3% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 16.0% | Industry Standard: 20%+ | Above 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 1.33x | Industry Standard: 1.0x+ | Above 1.0x | Measures asset utilization efficiency |
ASPIRA Cash Flow Quality — Operating & Free Cash Flow
Aspira Pathlab operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹2 Cr | ₹2 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹1 Cr | ₹1 Cr | Positive Free Cash Flow | 8/10 |